PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Amitriptylinoxide→

Amitriptylinoxide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
4317-14-0
Molecular formula
C20H23NO
Molecular weight
293.4 g/mol
Drug class
Tricyclic antidepressant-related N-oxidenoradrenergic and serotonergic reuptake inhibitor (historical)
Mechanism of action
Amitriptylinoxide is related to amitriptyline and is metabolised to active tricyclic antidepressant species. The pharmacology is associated with inhibition of serotonin and noradrenaline reuptake and antagonism at histamine, muscarinic and alpha-adrenergic receptors; current clinical mechanism and availability are limited.
Indications / reported uses
  • Historical treatment of depressive disorders in countries where amitriptylinoxide products were authorised; current marketed status and indications require local verification

Sources: NLM MeSH — Amitriptylinoxide · PubMed — Amitriptylinoxide antidepressant pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Amitriptylinoxide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Amitriptylinoxide Permitted Daily Exposure (PDE) report (the Amitriptylinoxide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Amitriptylinoxide Occupational Exposure Limit (OEL) report (the Amitriptylinoxide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.